Philip Mizell
Psychiatry · Little Rock, ARNPI 1174548366
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 253 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 15.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,337 and has fallen 51.8% since, to $644 in 2023.
Across 253 payments — averaging $18.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$687
- Takeda Pharmaceuticals U.S.A., Inc.$685
- Johnson & Johnson$480
- Sunovion Pharmaceuticals Inc.$403
- Vanda Pharmaceuticals Inc.$306
- AbbVie$226
- plus $2K from 19 others
What the payments were for
- Food & beverage$4,569100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 39 | $687 |
| Takeda Pharmaceuticals U.S.A., Inc. | 35 | $685 |
| Johnson & Johnson | 24 | $480 |
| Sunovion Pharmaceuticals Inc. | 22 | $403 |
| Vanda Pharmaceuticals Inc. | 18 | $306 |
| AbbVie(2 entities) | 17 | $226 |
| Ironshore Pharmaceuticals Inc. | 14 | $221 |
| Alkermes, Inc. | 11 | $218 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $206 |
| Teva Pharmaceuticals USA, Inc. | 11 | $198 |
| Avanir Pharmaceuticals, Inc. | 6 | $114 |
| Bausch Health US, LLC | 6 | $112 |
| Axsome Therapeutics, Inc. | 6 | $111 |
| Corium, LLC | 6 | $107 |
| Tris Pharma Inc | 5 | $93 |
| Neurocrine Biosciences, Inc. | 5 | $75 |
| Lundbeck LLC | 3 | $53 |
| Vertical Pharmaceuticals, LLC | 3 | $52 |
| Idorsia Pharmaceuticals US Inc | 3 | $48 |
| Jazz Pharmaceuticals Inc. | 2 | $43 |
| Neuronetics, Inc. | 2 | $40 |
| Eisai Inc. | 2 | $33 |
| Supernus Pharmaceuticals, Inc. | 2 | $33 |
| Merck | 1 | $14 |
| Almatica Pharma LLC | 1 | $13 |
How this compares
$4,569 in reported general payments places this provider in the 85th percentile of 235 psychiatry providers in Arkansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Omeprazole | 14 | $68 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Little Rock
- Leslie SmithLittle Rock$766K
- Tad TillemansLittle Rock$656K
- Paul WylieLittle Rock$54K
- Margaret WeissLittle Rock$29K
- Duong NguyenLittle Rock$14K
- Richard FlaniginLittle Rock$5K
- Robert FarrellLittle Rock$4K
- Pawel KuryloLittle Rock$4K
- Gintaras AukstuolisLittle Rock$4K
- Charles LewisLittle Rock$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.